





# Letter to the Editor, International Journal of COPD [Response to Letter]

This article was published in the following Dove Press journal:  
*International Journal of Chronic Obstructive Pulmonary Disease*

Montserrat Llordés <sup>1</sup>  
 Angeles Jaen <sup>2</sup>  
 Elba Zurdo <sup>1</sup>  
 Montserrat Roca<sup>1</sup>  
 Inmaculada Vazquez<sup>1</sup>  
 Pere Almagro <sup>3</sup>

On Behalf of the EGARPOC  
collaboration group

<sup>1</sup>Terrassa Sud Primary Care Center,  
Hospital Universitari Mutua Terrassa,  
University of Barcelona, Barcelona, Spain;  
<sup>2</sup>Fundació Docència i Recerca Mutua  
Terrassa, Barcelona, Spain; <sup>3</sup>Internal  
Medicine Service, Hospital Universitari  
Mutua Terrassa, University of Barcelona,  
Barcelona, Spain

## Dear editor

We appreciate the observations of Prof. Miller and colleagues about our article recently published in the International Journal of COPD.<sup>1</sup> The authors feel that our conclusions are not supported by data, based on two main arguments.

The first is that concordant and discordant patients are different. This is obvious, and in fact, extensively detailed in our study. It seems that the authors erroneously suggest that our study is penalized by selection bias since concordant and discordant groups are quite dissimilar. In fact, we just compared two different ways of defining airway obstruction in the same prospective cohort, in a similar approach to that used by Prof. Miller et al in a previous publication.<sup>2</sup> Regrettably, in their study, the lack of longitudinal follow-up prevented drawing valid conclusions about the evolution of the patients. Our data suggest that LLN is usually a more restrictive criterion and may misclassify patients with less severe disease. This explains the differences observed during the follow-up in hospitalizations and the COPD mortality after age-adjustment. Our results and those of several previous articles confirm that some patients classified as non-obstructive and therefore without COPD by LLN in fact present severe exacerbations and COPD mortality during follow-up.<sup>3,4</sup>

The second argument is that in patients with advanced COPD, the FEV1/FVC ratio can become artificially increased by premature distal airway closure in the spirometric evaluation of vital capacity with forced spirometry. However, the statement that in our study deterioration of pulmonary function was analyzed by the decline of FEV1/FVC ratio is incorrect. The loss of pulmonary function was measured with FEV1 (see Figure 3). It is true that the annualized FEV1/FVC ratio decreased more in discordant patients during follow-up. Nevertheless, the most relevant data concerning this argument—and not mentioned by the authors of the letter—is that 81% of discordant patients in the initial spirometry became concordant during follow-up. Since the two spirometric measures were performed in a similar manner, the fact that a considerable proportion of initially discordant patients developed obstruction by both criteria during the follow-up suggests that the exclusive use of LLN delayed the diagnosis. In our opinion, this is independent of the premature distal airway closure, which in any case should be similar in the two spirometric measurements.

Finally, a few additional considerations. FR and LLN are two ways to artificially divide a continuous variable (FEV1/FVC), and therefore rather than two different diagnostic criteria, FR and LLN represent two different points to dichotomize the

Correspondence: Montserrat Llordés  
Terrassa Sud Primary Care Center,  
Hospital Universitari Mutua Terrassa,  
Avenida Santa Eulàlia s/n, Terrassa,  
Barcelona 08223, Spain  
Tel +34 93 785 51 61  
Fax +34 93 731 49 52  
Email mllordes@mutuaterrassa.cat

same variable. Since COPD is a progressive disease, before reaching the formal threshold of airway obstruction, either by FR or LLN, FEV1/FVC must decline progressively. It is well-known that many non-obstructive patients had radiological involvement on CT preceding by years the accepted definition of airway obstruction, in what some authors have labelled “pre-COPD”.<sup>5,6</sup> In other words, in the absence of a biomarker, COPD is diagnosed when functional (airway obstruction) or radiological involvement becomes evident. For this reason, we compare two different cutoffs for the same variable, our conclusions are prudent - LLN seems to be less useful for COPD diagnosis in primary care - and we do not state at any point that our data “clearly demonstrate” that FR is superior to LLN, as the authors of the letter suggest.

## Disclosure

Pere Almagro reports grants from AstraZeneca and SEPAR, personal fees from Chiesi, Boehringer Ingelheim, and GlaxoSmithKline, travel support from Rovi and Esteve, unrelated to the submitted study. Montse Llordés reports speaker fees from Boehringer-Ingelheim, Glaxo, and

Gebro, outside the submitted work. The authors report no other conflicts of interest in this communication.

## References

1. Llordés M, Jaen A, Zurdo E, Vazquez I, Almagro P. Fixed ratio versus lower limit of normality for diagnosing COPD in primary care: long-term follow-up of EGARPOC Study. *J COPD*. 2020;15:1403–1413.
2. Miller MR, Haroon S, Jordan RE, et al. Clinical characteristics of patients newly diagnosed with COPD by the fixed ratio and lower limit of normal criteria: a cross-sectional analysis of the TargetCOPD trial. *Int J Chron Obstruct Pulmon Dis*. 2018;13:1979–1986. doi:10.2147/COPD.S146914
3. Bhatt SP, Balte PP, Schwartz JE, et al. Discriminative accuracy of FEV1: FVC thresholds for COPD-related hospitalization and mortality. *JAMA*. 2019;321(24):2438–2447. doi:10.1001/jama.2019.7233
4. Murphy DE, Panos RJ. Diagnosis of COPD and clinical course in patients with unrecognized airflow limitation. *Int J Chron Obstruct Pulmon Dis*. 2013;8:199–208. doi:10.2147/COPD.S39555
5. Arjomandi M, Zeng S, Barjaktarevic I, et al. Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS. *Eur Respir J*. 2019;54(4):1802214. doi:10.1183/13993003.02214-2018
6. Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. *N Engl J Med*. 2019;381(13):1257–1266. doi:10.1056/NEJMra1900500

Dove Medical Press encourages responsible, free and frank academic debate. The content of the International Journal of Chronic Obstructive Pulmonary Disease ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the International Journal of Chronic Obstructive Pulmonary Disease editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

## Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management

protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>